Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.
Health technology assessment agencies are struggling to evaluate drugs on the basis of evidence generated for early approvals, says AstraZeneca.
Accelerated access mechanisms that aim to get medicines to the market more quickly do not necessarily mean earlier access for patients, according to interim findings from a London School of Economics study.
Free trade talks between the EU and South American countries in the Mercosur trade bloc are set to resume on Nov. 6 in Brasilia. Critics of the EU proposals on intellectual property say they would mean Brazil spending billions more on medicines.
The BeNeLuxA coalition shows that “resetting the balance of power” is possible to give governments more clout in pricing negotiations, says the European Public Health Alliance.
An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.